Display for pump

Information

  • Patent Grant
  • 11488549
  • Patent Number
    11,488,549
  • Date Filed
    Monday, September 28, 2020
    3 years ago
  • Date Issued
    Tuesday, November 1, 2022
    a year ago
Abstract
An apparatus comprising a pump configured to deliver insulin, a processor, and a user interface including a color display. Color on the display can be used to bring a user's attention to a change in status of the device or a detected change in status of the patient.
Description
BACKGROUND

People who suffer from diabetes require insulin to keep their blood glucose level as close as possible to normal levels. It is essential for people with diabetes to manage their blood glucose level to within a normal range. Complications from diabetes can include heart disease (cardiovascular disease), blindness (retinopathy), nerve damage (neuropathy), and kidney damage (nephropathy). Insulin is a hormone that reduces the level of blood glucose in the body. Normally, insulin is produced by beta cells in the pancreas. In non-diabetic people, the beta cells release insulin to satisfy two types of insulin needs. The first type is a low-level of background insulin that is released throughout the day. The second type is a quick release of a higher-level of insulin in response to eating. Insulin therapy replaces or supplements insulin produced by the pancreas.


Conventional insulin therapy typically involves one or two injections a day. The low number of injections has the disadvantage of allowing larger variations in a person's insulin levels. Some people with diabetes manage their blood glucose level with multiple daily injections (MDI). MDI may involve more than three injections a day and four or more blood glucose tests a day. MDI offers better control than conventional therapy. However, insulin injections are inconvenient and require a diabetic person to track the insulin doses, the amount of carbohydrates eaten, and their blood glucose levels among other information critical to control.


It is important for a diabetic person to be treated with the proper amount of insulin. As discussed previously, high blood sugar can lead to serious complications. Conversely, a person with low blood sugar can develop hypoglycemia. Ideally, insulin therapy mimics the way the body works. An insulin pump is one way to mimic the body's insulin production. An insulin pump can provide a background or basal infusion of insulin throughout the day and provide a quick release or bolus of insulin when carbohydrates are eaten. If a person develops high blood sugar, a correction bolus can be delivered by the pump to correct it. While insulin pumps improve convenience and flexibility for a diabetic person, they can be sophisticated devices. Some insulin pumps can be difficult to program. It is desirable for an insulin pump to have features that make the pump more convenient or more effective for the patient to use.


Overview

This document discusses, among other things, devices and methods for assisting a diabetic person manage insulin therapy. A device example includes a pump configured to deliver insulin, a processor, and a user interface that includes a bistable display. A display element of the bistable display is placed in one of two stable orientations upon application of a biasing voltage. The display element stays in the stable orientation when the biasing voltage is removed. The processor includes a display module configured to display a non-blank reversion display screen on the bistable display when no input is received at the user interface after a specified time duration, and to recurrently change the reversion display screen until input is received at the user interface.


A method example includes providing a bistable display on a device having an insulin pump, reverting the display to a non-blank reversion display screen when no input is received at a user interface after a specified time duration, and recurrently changing the reversion display screen until input is received at the user interface.


This section is intended to provide an overview of subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the subject matter of the present patent application.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B illustrate portions of a device that includes an insulin pump.



FIG. 2 is a flow diagram of a method of presenting an insulin pump display to a user.



FIG. 3 is a block diagram of portions of an embodiment of an insulin pump device.



FIG. 4 is a block diagram of portions of another embodiment of an insulin pump device.



FIG. 5 shows an illustration of an example user interface with a display screen.



FIG. 6 is a flow diagram of another method of presenting an insulin pump display to a user.



FIG. 7 is a block diagram of portions of an embodiment of an insulin pump device.



FIG. 8 shows a flow diagram of another method of presenting an insulin pump display to a user.



FIG. 9 is a block diagram of portions of an embodiment of system for providing a display for an insulin pump device.



FIG. 10 is a flow diagram of another method of presenting a display for an insulin pump device.



FIG. 11 is a block diagram of portions of an embodiment of an insulin pump device having an alternative display.



FIG. 12 is a flow diagram of another method of presenting a display for an insulin pump device.





DETAILED DESCRIPTION

Insulin pump features may assist an insulin pump user in being more effective in treating their diabetes. FIGS. 1A and 1B illustrate portions of a device 100 that includes an insulin pump. The device 100 includes a cassette or cartridge of insulin. The cartridge is connectable to infusion tubing 140 connectable to a patient such as by a Luer lock 145 or infusion set 142. The device 100 includes a display 102 and a user interface that may include the display 102 and include one or more keys 104. Because proper use of an insulin pump often requires a user to go through a learning curve to properly treat their diabetes using the pump, it is desirable for a pump to provide assistance to the user in operating the pump, whether the user is a diabetic patient, a caregiver, or a clinician. Device displays are a useful way to provide information to the user.


Bistable Display

Ambulatory insulin pumps are typically battery powered. It is desirable to reduce power consumption in an ambulatory insulin pump device to extend the lifetime of the battery power source. Displays for the insulin pump devices typically require power to maintain the display. For example, organic light emitting diodes (OLEDs) require constant power source to generate light. Liquid crystal displays (LCDs) typically require a refresh cycle to periodically update the display. LCDs may also require backlighting to illuminate pixels of the display. These examples require power to maintain the display even if the information on the display does not change.


In a bistable display, a display element (e.g., a pixel or a subpixel) is placed in one of two stable orientations upon application of a biasing voltage, and the display element stays in the stable orientation when the biasing voltage is removed. Thus, a bistable display mainly requires power only when changing the orientation of the display element, and requires little or no power to maintain the orientation.


An example of a bistable display is an electrophoretic display (EPD). In an EPD, particles in the display acquire charge from the biasing voltage. The polarity of the voltage determines whether the charged particle will have a black appearance (the first stable orientation) or white appearance (the second stable orientation). Ambient reflected light is used to read the display similar to the way ambient light is used to read a newspaper. EPDs are sometime referred to as electronic paper (e-paper) or electronic ink (e-ink).


Another example of a bistable display is an interferometric modulator (IMOD) display. In some embodiments of an interferometric modulator display, application of a voltage causes a display element to have black appearance (the first stable orientation), and application of a lower voltage causes the display to appear bright and colored (the second stable state). In a bichrome display, the display element is a pixel and the bias voltage is applied to a pixel. In a color display, a color pixel is comprised of a grid of display elements called sub-pixels and the bias voltage is applied to a sub-pixel. The sub-pixels exhibit different colors when the lower voltage is applied and produce the same color (e.g., black) when the bias voltage is applied. Together, the sub-pixels provide a full color display using spatial dithering. A description of IMOD displays is found in U.S. Pat. No. 7,042,643, “Interferometric Modulation of Radiation,” filed Feb. 19, 2002, which is incorporated herein in its entirety.


Because a bistable display requires little or no power to maintain the display, the display will likely appear the same whether the insulin pump is working or the insulin pump has malfunctioned. This may make it difficult for an insulin pump user to notice when the device has malfunctioned.



FIG. 2 is a flow diagram of a method 200 of presenting an insulin pump display to a user. At block 205, a bistable display is provided on a device having an insulin pump. The display is bistable because a display element (e.g., a pixel or sub-pixel) may be placed in one of two stable orientations upon application of a biasing voltage, and the display element stays in the stable orientation when the biasing voltage is removed.


At block 210, the bistable display reverts to a non-blank reversion display screen when no input is received at a user interface of the insulin pump device after a specified time duration. For example, the reversion screen may be an icon from the manufacturer or a photo the user downloads into the insulin pump device. However, because of the nature of a bistable display, a user would not be able to notice from a simple reversion screen whether the device is still functioning properly.


At block 215, the reversion display screen is recurrently changed until input is received at the user interface. In some embodiments, recurrently changing the reversion display screen may include recurrently changing from one of a plurality of reversion display screens to another of the plurality of display screens. In some embodiments, recurrently changing the reversion display screen may include recurrently producing an animated effect on a single reversion display screen. In some embodiments, recurrently changing the reversion display screen may include switching among several display screens to create an animated effect, such as sequentially displaying animation frames to produce an animated effect. Use of reversion screens may assist a user in operating their insulin pump device.



FIG. 3 is a block diagram of portions of an embodiment of an insulin pump device 300. The insulin pump device 300 includes a pump 305 configured to deliver insulin and a user interface 310. The pump 305 may be a positive displacement pump. Descriptions of an example of a medication pump to deliver insulin are found in Vilks et al., “Cartridge and Rod for Axially Loading a Medication Pump,” U.S. Pat. No. 7,033,338, filed Feb. 28, 2002, which is incorporated herein by reference in its entirety. The pump 305 may drive a plunger in a removable insulin cartridge to deliver the insulin.


The user interface 310 includes a bistable display 315. In some embodiments, the bistable display 315 includes an interferometric modulation display. In some embodiments, the bistable display 315 includes an electrophoretic display. In some embodiments, the bistable display 315 includes an EPD. The substrate for the EPD may be made of flexible plastic. This provides a robust and thin display for the insulin pump device 300.


The insulin pump device 300 also includes a processor 320. The processor 320 may be a microprocessor, digital signal processor (DSP), or other type of processor. The processor 320 is configured to perform or execute a function or functions. Such functions correspond to modules to provide features integral to the first device. Modules may be software, hardware, firmware or any combination thereof. Multiple functions may be performed in one or more modules. In some embodiments, software or firmware is provided on a computer readable medium. The computer readable medium includes instructions therein, which when processed (such as by the processor 320 for example) results in a device performing the functions described herein. Examples of a computer readable medium include a compact disc (CD), memory stick, or remote storage accessible via a communication network such as the interne or a cell phone network.


The processor 320 is communicatively coupled to the pump 305 and the user interface 310. The communicative coupling allows the processor 320 to exchange electrical signals with the pump 305 and the user interface 310 even though intervening circuitry may be present. The processor 320 includes a display module 325 configured to display a non-blank reversion display screen on the bistable display 315 when no input is received at the user interface 310 after a specified time duration, and to recurrently change the reversion display screen until input is received at the user interface.


In some embodiments, the display module 325 is configured to produce an animated effect on the reversion display screen. For example, the animated effect may be a moving icon. The display module 325 recurrently produces the animated effect on the reversion display screen until input is received at the user interface 310. At which point the display module 325 may change from the reversion screen display to a home menu display.


In an illustrative example, the moving icon may be a clock and the animated effect may be moving hands of the clock. The display module 325 periodically produces the animated effect by moving the hands of the clock to display time according to a timer of the processor. In some embodiments, the display module 325 is configured to display time on the reversion display screen by displaying numbers on the display screen and updating the numbers according to the time.


According to some embodiments, the insulin pump device 300 includes a memory 330 communicatively coupled to the processor 320. The memory 330 stores a plurality of reversion display screens, and the display module 325 is configured to display one of the plurality of reversion display screens when no input is received at the user interface after a specified time duration, and to recurrently change the reversion display screen from one of the plurality of reversion display screens to another of the plurality of reversion display screens while no input is received at the user interface 310. The reversion display screen would change after a time duration, such as every few seconds for example.


In some embodiments, the display module 325 is configured to change the reversion display screen in response to input received via the user interface. For example, as a test to verify the insulin pump device 300 is working properly, the reversion display screen would change when the user presses a specified user interface key or button. In another example, the user may use the user interface 310 to advance through several reversion display screen options and indicate a desired display screen. In certain embodiments, the memory 330 stores an indication that a reversion display screen is selected by a user. The display module 325 only displays one or more reversion screens selected by the user. In certain embodiments, one or more reversion screens are images downloaded by the user, such as photos for example. The display module 325 may display the images in a slide-show fashion.


Various events may cause the display module 325 to change the bistable display 315 from a reversion screen. In some embodiments, the display module 325 changes the bistable display 315 from the reversion display screen to a home menu when input is received at the user interface 310. In some embodiments, the display module 325 changes the bistable display 315 from the reversion display screen in response to a change in status of the insulin pump device 300. For example, the change in status may be related to a problem of the insulin pump device 300, such as an insulin cartridge containing less than a threshold level of insulin, a device battery having a capacity less than a threshold battery capacity value, or an indication that the insulin pump device is not operating correctly. The display module 325 may change to an alarm display screen to indicate a problem to the user, may change to a debug display screen to help the user determine the problem, or may display both an alarm display screen and a debug display screen.


In some embodiments, the display module 325 changes the reversion display screen in response to a detected change in a clinical status of a user. The change in clinical status may include at least one of a recent blood glucose reading being higher than a first threshold blood glucose value, a recent blood glucose reading being lower than the same threshold blood glucose value or a second threshold blood glucose value, the user exercising within a specified time period, the user eating within a specified time period, the user not eating within a specified time period, or the user having active insulin in their body. The display module 325 may change to an alarm display screen to indicate the change in clinical status to the user.


Custom Display Menus


Insulin pumps may be able to provide a variety of therapies and diagnostics for the user. Accessing the functions of the device may include navigating through several layers of device menus. It would be helpful to the user if the display menus are customized for the user. The menus may be automatically customized according to which functions are used most often, according to which functions are more appropriate for the users clinical status, or the menus may be manually customized by the user directly.



FIG. 4 is a block diagram of portions of an embodiment of an insulin pump device 400. The insulin pump device 400 includes a pump 405 configured to deliver insulin and a user interface 410 that includes a display 415. In some embodiments, the display 415 is a bistable display. The insulin pump device 400 also includes a processor 420 communicatively coupled to the pump 405 and the user interface 410. The processor 420 includes a menu display module 425. The menu display module 425 presents one of a plurality of device menus on the display 415.



FIG. 5 shows an illustration of an example user interface 510 with a display screen 515. The user interface 510 includes a keypad 540 including function keys 542 and scroll keys 544 or up/down keys. The display screen 515 shows an example display menu having menu items. The user interface 510 receives a selection of a menu item included in a display menu. Selecting a menu item causes the processor to perform an action, such as indicating a status of the insulin pump device, modifying an operation parameter, or initiating a device task.


The example display menu shown has a top portion 546 and a bottom portion 548. The top portion 546 may show a display banner 550 identifying the pump as “Mary's Pump”. The display banner 550 may be customized by the user via the keypad 540. The example display menu is one shown during active delivery of basil insulin. The display menu indicates basal insulin is being delivered at a rate of 1.15 units/hour according to a first basal schedule. The top portion 546 may present the name 552 of the active function and details of the function performed.


The bottom portion indicates the current function of the keys 542, 544. In the display shown, the pressing the left function key suspends the basal delivery. If delivery is suspended, the function of the left function key may change to activating the delivery. The right function key advances the display screen to a different display menu. The up/down keys retain the up/down function. For example, the scroll keys 544 may be used to highlight the name 552 of the active function in order to change from the first basal schedule.


The example display menu also shows a first icon 554 and a bar 556 to show the amount of insulin remaining in the insulin cartridge, and a second icon 558 and a bar 560 to indicate the remaining battery life. The example display menu also shows a third icon 562 to identify the display menu as the home menu or home page for the user.


Returning to FIG. 4, it was noted that the menu display module 425 presents one of a plurality of device menus on the display 415. The menu display module 425 arranges the device menus into an order for presentation according to user preference information. In some embodiments, the user preference information includes the frequency that certain menus are used. The menu display module 425 tracks device menu selections made via the user interface 410. The menu display module 425 then arranges the device menus into a presentation order according to a frequency with which device menus are used. For example, if the user frequently accesses the basal delivery display menu, the menu display module 425 moves the basal delivery display menu closer to the beginning of the order with which device menus are displayed.


According to some embodiments, the user preference information includes information regarding the clinical status of the user. The information may be entered into a memory 430 of the device via the user interface 410 or may be downloaded into the memory 430 via a communication port. The processor 420 receives the clinical status information and the menu display module 425 arranges the device menus into the presentation order according to the clinical status information.


For example, the clinical status information may indicate that the user has delayed gastric emptying. A user with delayed gastric emptying may use an extended or combination bolus of insulin. Descriptions of insulin pump devices that provide extended and combination boluses are found in Blomquist, U.S. patent application Ser. No. 11/679,712, “Carbohydrate Ratio Test Using Frequent Blood Glucose Input,” filed Feb. 27, 2007, which is incorporated herein by reference in its entirety. The menu display module 425 may make it more convenient for the user to access the display menu used to program and initiate an extended and/or combination bolus (e.g., the extended bolus menu may be presented before the standard bolus display menu).


In another example, the clinical status information may include an indication that the user has a high or low blood glucose reading. The menu display module 425 may make it more convenient (e.g., displayed sooner in a hierarchy) for the user to access a display menu that is used when measuring blood glucose. The menu display module 425 may also make it more convenient for the user to access the blood glucose measurement display menu if the user is performing basal rate testing. Descriptions of devices that automatically perform basal rate testing are found in Blomquist, U.S. patent application Ser. No. 11/685,617, “Basal Rate Test Using Frequent Blood Glucose Input,” filed Mar. 13, 2007, which is incorporated herein by reference in its entirety.


According to some embodiments, the processor 420 determines information regarding eating times of the user. The processor 420 may determine the information by receiving the information through a communication port or via a user interface. The processor 420 may determine the information by deducing the information regarding eating times from other programmed parameters, such as programmed meal boluses or programmed missed meal bolus alarms. In some embodiments the processor 420 may determine the information by learning the eating times of the user, such as by tracking the times a meal bolus is initiated for example.


The menu display module 425 arranges the device menus into the presentation order according to the eating times of the user. For example, based on the information, the menu display module 425 may arrange the display menus in anticipation of the user initiating a post-prandial blood glucose test, and make the blood glucose measurement display menu more convenient for the user to access.


According to some embodiments, the processor 420 includes a timing module 435. The menu display module 425 arranges the device menus into the presentation order according to a time of day. For example, the menu display module 425 may make it more convenient for the user to access a display menu used to program and/or initiate a meal or correction bolus based on time the user typically exercises or eats. In another example, if the user checks their blood glucose at a specific time of day, the menu display module 425 may make the blood glucose measurement display menu more convenient for the user to access at those times. In still another example, the user may disconnect the pump or change the insulin cartridge at specific times of day. The menu display module 425 may make the related display menus easier for the user to access at those times.


In some embodiments, the user enters the user preference information via the user interface. For example, the user enters an indication of which display menu she wishes to display as the home display menu. The processor 420 receives the user preference information and the menu display module 425 arranges the device menus into the presentation order according to the received user preference information.


The menu items included in a home menu are a subset of all available menu items. In some embodiments, the menu display module includes menu items in the home menu according to the user preference information. For example, the user may provide, via the user interface 410, an indication that the battery icon of FIG. 5 should be placed in the home menu. In certain embodiments, the processor 420 includes the timing module 435 and the user preference information includes a display reversion time duration. The menu display module 425 reverts from a displayed menu to the home menu when no displayed menu items are selected during the display reversion time duration.


In some embodiments, the menu display module 425 tracks device menu selections made via the user interface. The menu display module 425 includes menu items in the device home menu according to a frequency with which menu items are used. For example, if the user frequently checks how much insulin is remaining in the insulin cartridge, the menu display module 425 adds the insulin remaining icon to the home menu.


According to some embodiments, the insulin pump device 400 includes a memory 430 communicatively coupled to the processor to store a database of food options in association with a known amount of nutrient content. Nutrient content includes one or more of the amount of carbohydrates, fat, protein, or fiber in an amount of a type of food. The menu display module 425 displays food options in one or more display menus. The user indicates the food she is going to eat and the processor 420 may use the nutrient content for the indicated food option to determine an amount of insulin in a meal bolus or to determine a type of meal bolus for the user.


In some embodiments, the menu display module 425 is configured to track selections from the food database made by the user. The menu display module 425 may than arrange a viewing order of entries in the food database according to a frequency with which entries are selected. For example, if the user often selects pizza for lunch, the menu display module 425 may select that food option first when the food database menu is accessed at lunchtime.


In some embodiments, the user interface 410 includes a programmable tactile switch or button (e.g., tactile switch 564 in FIG. 5). The processor 420 is configured to initiate an action upon activation of the tactile switch. The processor action is specified in the user preference information. Thus, the tactile switch may be a generic switch or button until it is programmed by the user. For example, the tactile switch may be programmed to initiate a type of insulin bolus, to bring a specific display menu, or to activate a type of alarm provided by the insulin pump device 400.



FIG. 6 is a flow diagram of a method 600 of presenting an insulin pump display to a user. At block 605, a user interface is provided on a device having an insulin pump. The user interface includes a display. At block 610, user preference information is received into the device via the user interface. At block 615, a viewing order of a plurality of displayed device menus is arranged according to the user preference information.


Color Display


Information presented on a display is not of much use to the user if the user does not notice the information. Color on a display can be used to bring a user's attention to a change in status of the device or a detected change in status of the patient.



FIG. 7 is a block diagram of portions of an embodiment of an insulin pump device 700. The insulin pump device 700 includes a pump 705 configured to deliver insulin and a color display 715. In some embodiments, the color display 715 includes a color bistable display. The insulin pump device 700 also includes a processor 720 that comprises a display module 725 to display information related to clinical status of a user using a color indication and to change the color indication in response to a change in clinical status of the user.


Examples of a change in clinical status of the user include, among other things, a recent blood glucose reading being higher than a first threshold blood glucose value, a recent blood glucose reading being lower than the same threshold blood glucose value or a second threshold blood glucose value, the user exercising within a specified time period, the user eating within a specified time period, the user not eating within a specified time period, and the user having active insulin in their body.


Examples of change in a color indication used in the display 715 include, among other things, a change in a display background color, a change in a display backlight color, a change in a text color, and a color flashing indicator. The display module 725 changes the color indication when the clinical status changes. For example, the display module 725 may use a first display color when the user selects an insulin bolus display menu and there is no active insulin in the user's body, and uses a second display color when the user selects an insulin bolus display menu and there is active insulin in the user's body. In another example, the display module 725 may flash the insulin bolus display menu with the first or second display color when there is active insulin in the user's body.


In another embodiment, the change in a color indication is a gradual change. For example, the display module 725 may gradually change the color indication according to an amount of insulin that is active in the user, such as by gradually fading from the second display color to the first display color as the amount of active insulin decreases.


According to some embodiments, the display module 725 generates a device report on the color display 715. The processor 720 stores events in a memory integral to or communicatively coupled to the processor 720. The events may include historical insulin delivery information, recorded use parameters, and changes in the clinical status of the user. The display module 725 displays the device report and uses a color indication to show a change in clinical status.


In some embodiments, the insulin pump device includes a communication port 765 communicatively coupled to the processor 720. In some embodiments, the communication port 765 is a wireless port, such as an infrared (IR) port or a radio frequency (RF) port for example. In some embodiments, the communication port 765 is a wired port, such as a serial port for example. The processor 720 communicates the generated device report to a second separate device via the communication port, such as for printing of the device report or for displaying the device report for example.



FIG. 8 shows a flow diagram of a method 800 of presenting an insulin pump display to a user. At block 805, a color display is incorporated into a device that includes a pump configured to deliver insulin. At block 810, a display color is changed in response to a change in clinical status of the user.


Returning to FIG. 7, according to some embodiments, the display module 725 is configured to change the color indication in response to a change in status of the insulin pump device. Examples of a change in status of the insulin pump device include, among other things, an insulin cartridge containing less than a threshold level of insulin, a device battery having a capacity less than a threshold battery capacity value, or an indication that the insulin pump device (e.g., the pump 705 itself) has stopped operating.



FIG. 8 also shows a flow diagram of a second method 820 of providing an insulin pump display to a user. At block 825, a color display is incorporated into a device that includes a pump configured to deliver insulin. In some embodiments, a color bistable display is incorporated into the device. At block 830, a display color is changed in response to a change in status of the insulin pump device.


Alternative Remote Display


Insulin pumps continue to decrease in size as technology advances. However, bigger displays are sometimes desirable for training on the devices or if the user has impaired vision.



FIG. 9 is a block diagram of portions of an embodiment of system 900 for providing a display for an insulin pump device. The system 900 comprises an insulin pump device 901 and a display device 902. The insulin pump device 901 includes a pump 905 configured to deliver insulin, a user interface 910, a communication port 965, and a first processor 920 communicatively coupled to the pump 905, the user interface 910, and the communication port 965.


The display device 902 includes a communication port 970, a monitor 975, and a second processor 980 communicatively coupled to the communication port 970 and the monitor 975. The first processor 920 includes a display data module 925 that communicates display information from the insulin pump device to the display device 902 via the communication ports 965, 970.


In some embodiments, the communication ports 965, 970 are wireless ports, such as an IR ports or RF ports for example. The insulin pump device 901 and the display device may communicate using a wireless protocol such as Bluetooth protocol, the WiFi protocol, or the infrared data (IrDA) protocol. In some embodiments, the communication ports 965 are wired ports, such as serial ports for example. The insulin pump device 901 and the display device may communicate using the universal serial bus (USB) protocol.


Input signals received at the user interface 910 change operation of the insulin pump device 901. These changes are reflected on the monitor 975 of the display device 902. The data display module 925 converts input received via the user interface 910 into changes to a display, and communicates updated display information according to the received input to the display device 902. The second processor receives the display information via the communication port 970 and displays a user menu for the insulin pump device 901 on the monitor 975.


Examples of display information communicated by the display data module 925 to the display device 902 include, among other things, an indication of status of the insulin pump device, a prompt to initiate a task by the insulin pump device, or an operation parameter of the insulin pump device. In some embodiments, the display data module 925 communicates, for display on the display device 902, instructions for using the insulin pump device 901. This is useful for training a new user to operate the insulin pump device 901.


The monitor 975 may be a larger display than is available for the insulin pump device 901, and the second processor 980 may display an enlarged version of the user menu for the insulin pump device 901 on the monitor 975. This allows the user to easily see how the input into the user interface 910 has effected operation of the insulin pump device 901. In some embodiments, the monitor 975 is a video monitor and the display device 902 includes a video adapter 985 communicatively coupled to the second processor 980 and the video monitor to convert the received display information to a video format for display on the video monitor.


According to some embodiments, the display device 902 includes a second user interface 990 communicatively coupled to the second processor 980. The second processor 980 manipulates the user menu for the insulin pump device 901 on the monitor 975 according to input received via the second user interface 990. Thus, the user menu displayed on the display device 902 may be changed according to input received via the second user interface 990. For example, the second user interface 990 allows the second processor to change a contrast of the user menu for the insulin pump device displayed on the monitor, a size of the user menu for the insulin pump device displayed on the monitor, or a color used in the displaying the user menu for the insulin pump device on the monitor.


According to some embodiments, the first processor 920 includes a report module 995 to generate a device report. As described previously, the device report may include historical insulin delivery information, recorded use parameters, and changes in the clinical status of the user. The display data module 925 communicates the device report to the display device 902 for display.



FIG. 10 is a flow diagram of a method 1000 of presenting a display for an insulin pump device. At block 1005, a user interface is provided on a device having an insulin pump. At block 1010, display information is communicated from the insulin pump device to a second separate device. At block 1015, displaying a user menu for the insulin pump device is displayed on the second device using the display information. In some embodiments, the display information is converted to a video format at the second device and displayed on a video monitor. At block 1020, a menu selection is received at the user interface of the insulin pump. The menu selection is a menu item displayed on second device. The menu selection may be to change an operating parameter, initiate insulin therapy, display a device status, or run a device diagnostic for example. At block 1025, updated display information is communicated to the second device according to the menu selection. At block 1030, the user menu displayed on the second device is updated using the updated display information.



FIG. 11 is a block diagram of portions of an embodiment of an insulin pump device 1100 having an alternative display. The insulin pump device 1100 includes a pump 1105 configured to deliver insulin, a video output port 1165, and a processor 1120 communicatively coupled to the pump 1105 and the video output port 1165. The processor 1120 includes a display data module 1125 that communicates video display information via the video output port to a second separate device, such as a video monitor 1175 for example. The insulin pump device 100 is connected to the monitor 1175 via the video output port 1165.


In some embodiments, the video output port 1165 is an analog video output. The display data module 1125 provides the video display information in an analog video format at the video output port 1165. Examples of analog video formats provide by the display data module 1125 include, among other things, composite video, S video, component video, and VGA. In some embodiments, the video output port 1165 is a digital video output. The display data module 1125 provides the video display information in a digital format at the video output port 1165. Examples of digital video formats provide by the display data module 1125 include, among other things, High Definition Multimedia Interface (HDMI) and Digital Visual Interface (DVI).


In some embodiments, the insulin pump device 1100 includes a user interface 1110. The display data module 1125 converts input received via the user interface 1110 into changes to a display and communicates updated video display information according to the received input via the video output port. In this way, the monitor 1175 acts as a display for the insulin pump device 1100. The user interface 1110 may include a display screen on the insulin pump device 1100. The display data module 1125 may provide updated data to both the user interface display and the monitor 1175. The monitor 1175 may thereby function as an enlarged version of the device display screen.


In some embodiments, the insulin pump device 1100 includes a memory 1130. The memory 1130 stores one or more files containing video data. The display data module 1125 plays a video data file via the video output port 1165. The video data file may include training material, and the video data file provides a video tutorial to the user on the monitor 1175 when played. In some embodiments, the insulin pump device 1100 plays the video data file in response to an input received at the user interface 1110, such as an indication of menu selection for example.


In some embodiments, the insulin pump device 1100 includes an audio port 1180. The memory 1130 may store one or more files containing audio data. The display data module 1125 is configured to play the audio data file via the audio port 1180 in association with playing the video data file. In some embodiments, if the format of the file allows audio and video to be combined, the audio and video files may be provided by a single output port. The audio file may indicate a pump-related alarm or alert, or the audio file may accompany the training video.



FIG. 12 is a flow diagram of another method 1200 of presenting a display for an insulin pump device. At block 1205, a video output port is provided on a device having an insulin pump. At block 1210, video display information is communicated from the insulin pump device to a second separate device via the video output port. The second device may be a monitor or a television depending on the video format. Thus, the pump is a video driver for the second device.


As further shown in FIG. 12, in some embodiments the method 1200 includes, at block 1215, providing a user interface on the insulin pump device. At block 1220, providing a memory is provided on the insulin pump device to store one or more video data files. At block 1225, the video data file is played via the video output port in response to an input received at the user interface.


The above detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention can be practiced. These embodiments are also referred to herein as “examples.” All publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference(s) should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.


In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one, independent of any other instances or usages of “at least one” or “one or more.” In this document, the term “or” is used to refer to a nonexclusive or, such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.


Method examples described herein can be machine or computer-implemented at least in part. Some examples can include a computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples. An implementation of such methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for performing various methods. The code may form portions of computer program products. Further, the code may be tangibly stored on one or more volatile or non-volatile computer-readable media during execution or at other times. These computer-readable media may include, but are not limited to, hard disks, removable magnetic disks, removable optical disks (e.g., compact disks and digital video disks), magnetic cassettes, memory cards or sticks, random access memories (RAM's), read only memories (ROM's), and the like.


The above description is intended to be illustrative, and not restrictive. For example, the above-described examples (or one or more aspects thereof) may be used in combination with each other. Other embodiments can be used, such as by one of ordinary skill in the art upon reviewing the above description. The Abstract is provided to comply with 37 CFR § 1.72(b), to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims
  • 1. An ambulatory infusion pump system, comprising: a user interface including a color display configured to display information to a user in a plurality of colors;a memory configured to store parameters relating to treatment of the user with an ambulatory infusion pump, including one or more thresholds related to glucose levels of the user; anda processor configured to control the information displayed on the color display, the processor further configured to: receive information relating to glucose levels of the user;display information relating to a recent glucose level of the user on a portion of the display in a first color;compare the information relating to glucose levels of the user to the one or more thresholds related to glucose levels of the user; andchanging the information relating to a recent glucose level of the user on the portion of the color display from the first color to a second color at the time when a glucose level of the user passes one of the one or more thresholds related to glucose levels of the user, andwherein the processor is further configured to alter a color of a portion of the color display based on a change in status of the ambulatory infusion pump.
  • 2. The ambulatory infusion pump system of claim 1, further comprising an ambulatory infusion pump.
  • 3. The ambulatory infusion pump system of claim 2, wherein the user interface is part of the ambulatory infusion pump.
  • 4. The ambulatory infusion pump system of claim 2, wherein the user interface is part of a device that is separate from the ambulatory infusion pump.
  • 5. The ambulatory infusion pump system of claim 1, wherein comparing the information relating to glucose levels of the user to the one or more thresholds related to glucose levels of the user includes comparing glucose levels of the user to a high glucose threshold and to a low glucose threshold.
  • 6. The ambulatory infusion pump system of claim 5, wherein the processor is configured to alter the color of the portion of the color display when the glucose level of the user is higher than the high glucose threshold.
  • 7. The ambulatory infusion pump system of claim 5, wherein the processor is configured to alter the color of the portion of the color display when the glucose level of the user is lower than the low glucose threshold.
  • 8. The ambulatory infusion pump system of claim 1, wherein altering the color of the portion of the color display includes altering a color of text on the color display.
  • 9. The ambulatory infusion pump system of claim 1, wherein altering the color of the portion of the color display includes altering a color of a portion of a background of the color display.
  • 10. The ambulatory infusion pump system of claim 1, wherein altering the color of the portion of the color display includes displaying a color flashing indicator.
  • 11. An ambulatory infusion pump system, comprising: a user interface including a color display configured to display information to a user in a plurality of colors;a memory configured to store parameters relating to treatment of the user with an ambulatory infusion pump; anda processor configured to control the information displayed on the color display, the processor further configured to: receive information relating to a clinical status of the user;display information relating to the clinical status of the user on a portion of the color display in a first color;compare the information relating to the clinical status of the user to the parameters relating to treatment of the user; andchanging the portion of the color display from the first color to a second color at the time of a change in the clinical status of the user, wherein the processor is further configured to alter a color of a portion of the color display based on a change in status of the ambulatory infusion pump.
  • 12. The ambulatory infusion pump system of claim 11, further comprising an ambulatory infusion pump.
  • 13. The ambulatory infusion pump system of claim 12, wherein the user interface is part of the ambulatory infusion pump.
  • 14. The ambulatory infusion pump system of claim 12, wherein the user interface is part of a device that is separate from the ambulatory infusion pump.
  • 15. The ambulatory infusion pump system of claim 11, wherein the change in clinical status of the user is a glucose level exceeding a high glucose threshold or below a low glucose threshold.
  • 16. The ambulatory infusion pump system of claim 11, wherein the change in clinical status of the user relates to an amount of active insulin in the user's body.
  • 17. The ambulatory infusion pump system of claim 11, wherein altering the color of the portion of the color display includes altering a color of text on the color display.
  • 18. The ambulatory infusion pump system of claim 11, wherein altering the color of the portion of the color display includes altering a color of a portion of a background of the color display.
  • 19. The ambulatory infusion pump system of claim 11, wherein altering the color of the portion of the color display includes displaying a color flashing indicator.
  • 20. The ambulatory infusion pump system of claim 11, wherein the change in status of the ambulatory infusion pump relates to a level of insulin in the ambulatory infusion pump.
  • 21. The ambulatory infusion pump system of claim 11, wherein the change in status of the ambulatory infusion pump relates to a battery level of the ambulatory infusion pump.
RELATED APPLICATIONS

This application is a continuation of application Ser. No. 16/401,684 filed May 2, 2019, which in turn is a continuation of application Ser. No. 15/407,955 filed Jan. 17, 2017, now U.S. Pat. No. 10,726,100 issued Jul. 28, 2020, which in turn is a continuation of application Ser. No. 13/242,116 filed Sep. 23, 2011, now abandoned, which in turn is a division of application Ser. No. 12/114,033 filed May 2, 2008, now U.S. Pat. No. 8,133,197 issued Mar. 13, 2012, which is hereby fully incorporated herein by reference.

US Referenced Citations (688)
Number Name Date Kind
2968804 Buffington Jan 1961 A
3555286 Cote Jan 1971 A
3603152 Alibert et al. Sep 1971 A
3777165 Bryant et al. Dec 1973 A
3809871 Howard et al. May 1974 A
3923060 Ellinwood, Jr. Dec 1975 A
3942526 Wilder et al. Mar 1976 A
3985133 Jenkins et al. Oct 1976 A
4027536 Heggie Jun 1977 A
T961004 Horton Aug 1977 I4
4080967 O'Leary Mar 1978 A
4091550 Schrenk et al. May 1978 A
4098267 Stein et al. Jul 1978 A
4137913 Georgi Feb 1979 A
4141252 Lodge Feb 1979 A
4146029 Ellinwood, Jr. Mar 1979 A
4174637 Mulzet et al. Nov 1979 A
4184815 Casson et al. Jan 1980 A
4191184 Carlisle Mar 1980 A
4210138 Jess et al. Jul 1980 A
4213454 Shim Jul 1980 A
4217993 Jess et al. Aug 1980 A
4236880 Archibald Dec 1980 A
4270532 Franetzki et al. Jun 1981 A
4279188 Scott Jul 1981 A
4280136 Kashima et al. Jul 1981 A
4282872 Franetzki et al. Aug 1981 A
4299218 Knigge et al. Nov 1981 A
4299541 Ohara et al. Nov 1981 A
4308866 Jelliffe et al. Jan 1982 A
4309993 Brown Jan 1982 A
4311377 Matteson Jan 1982 A
4314227 Eventoff Feb 1982 A
4314228 Eventoff Feb 1982 A
4315238 Eventoff Feb 1982 A
4320757 Whitney et al. Mar 1982 A
4368645 Glenn et al. Jan 1983 A
4369780 Sakai Jan 1983 A
4370983 Lichtenstein Feb 1983 A
4373525 Kobayashi Feb 1983 A
4373527 Fischell Feb 1983 A
4385630 Gilcher et al. May 1983 A
4385958 Long May 1983 A
RE31315 Jenkins et al. Jul 1983 E
4392849 Petre et al. Jul 1983 A
4394862 Shim Jul 1983 A
4395259 Prestele et al. Jul 1983 A
4396977 Slater et al. Aug 1983 A
4398542 Cunningham et al. Aug 1983 A
4410322 Archibald Oct 1983 A
4413314 Slater et al. Nov 1983 A
4425661 Moses et al. Jan 1984 A
4431425 Thompson et al. Feb 1984 A
4443218 DeCant, Jr. et al. Apr 1984 A
4446344 Fiedler May 1984 A
4460355 Layman Jul 1984 A
4484479 Eckhardt Nov 1984 A
4489302 Eventoff Dec 1984 A
4490798 Franks et al. Dec 1984 A
4493704 Beard et al. Jan 1985 A
4494950 Fischell Jan 1985 A
4498843 Schneider et al. Feb 1985 A
4512013 Nash et al. Apr 1985 A
4520706 Deforeit Jun 1985 A
4526574 Pekkarinen Jul 1985 A
4529401 Leslie et al. Jul 1985 A
4530696 Bisera et al. Jul 1985 A
4534756 Nelson Aug 1985 A
4542532 McQuilkin Sep 1985 A
4550731 Batina et al. Nov 1985 A
4550748 Nunez Nov 1985 A
4557725 Heyne et al. Dec 1985 A
4559037 Franetzki et al. Dec 1985 A
4559038 Berg et al. Dec 1985 A
4559044 Robinson et al. Dec 1985 A
4561443 Hogrefe et al. Dec 1985 A
4562751 Nason et al. Jan 1986 A
4563179 Sakai Jan 1986 A
4565542 Berg Jan 1986 A
4578573 Flies et al. Mar 1986 A
4596575 Rosenberg et al. Jun 1986 A
4597754 Thill et al. Jul 1986 A
4601702 Hudson Jul 1986 A
4606353 Timm Aug 1986 A
4617014 Cannon et al. Oct 1986 A
4623331 Cewers et al. Nov 1986 A
4624661 Arimond Nov 1986 A
4627835 Fenton, Jr. Dec 1986 A
4627839 Young Dec 1986 A
4649499 Sutton et al. Mar 1987 A
4650469 Berg et al. Mar 1987 A
4652260 Fenton, Jr. et al. Mar 1987 A
4656603 Dunn Apr 1987 A
4658371 Walsh et al. Apr 1987 A
4671792 Borsanyi Jun 1987 A
4676776 Howson Jun 1987 A
4678408 Nason et al. Jul 1987 A
4681563 Deckert et al. Jul 1987 A
4685903 Cable et al. Aug 1987 A
4690673 Bloomquist Sep 1987 A
4692147 Duggan Sep 1987 A
4696671 Epstein et al. Sep 1987 A
4710163 Butterfield Dec 1987 A
4714462 DiDomenico Dec 1987 A
4722734 Kolln Feb 1988 A
D294733 Peterson et al. Mar 1988 S
4731051 Fischell Mar 1988 A
4731058 Doan Mar 1988 A
4731726 Allen, III Mar 1988 A
4739229 Heiler, Jr. Apr 1988 A
4741732 Crankshaw et al. May 1988 A
4745301 Michalchik May 1988 A
4747828 Tseo May 1988 A
4754401 Kaczynski et al. Jun 1988 A
4756706 Kerns et al. Jul 1988 A
4774029 Poulin Sep 1988 A
4775368 Iwatschenko Oct 1988 A
4778449 Weber et al. Oct 1988 A
4785799 Schoon et al. Nov 1988 A
4790816 Sundblom et al. Dec 1988 A
4799381 Tromp Jan 1989 A
4808161 Kamen Feb 1989 A
4808167 Mann et al. Feb 1989 A
4809697 Causey, III et al. Mar 1989 A
4810243 Howson Mar 1989 A
4810992 Eventoff Mar 1989 A
4816019 Kamen Mar 1989 A
4818186 Pastrone et al. Apr 1989 A
4826810 Aoki May 1989 A
4832033 Maher et al. May 1989 A
4836752 Burkett Jun 1989 A
4838856 Mulreany et al. Jun 1989 A
4838857 Strowe et al. Jun 1989 A
4842584 Pastrone Jun 1989 A
4846792 Bobo, Jr. et al. Jul 1989 A
4847764 Halvorson Jul 1989 A
4847990 Patrick Jul 1989 A
4850807 Frantz Jul 1989 A
4850972 Schulman et al. Jul 1989 A
4852581 Frank Aug 1989 A
4854324 Hirschman et al. Aug 1989 A
4856339 Williams Aug 1989 A
4863425 Slate et al. Sep 1989 A
4869722 Heyman Sep 1989 A
4871351 Feingold Oct 1989 A
4878896 Garrison et al. Nov 1989 A
4882575 Kawahara Nov 1989 A
4889132 Hutcheson et al. Dec 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
4901221 Kodosky et al. Feb 1990 A
4908017 Howson et al. Mar 1990 A
4914568 Kodosky et al. Apr 1990 A
4918930 Gaudet et al. Apr 1990 A
4919650 Feingold et al. Apr 1990 A
4925444 Orkin et al. May 1990 A
4927411 Pastrone et al. May 1990 A
4933873 Kaufman et al. Jun 1990 A
4942514 Miyagaki et al. Jul 1990 A
4943279 Samiotes et al. Jul 1990 A
4950235 Slate et al. Aug 1990 A
4950244 Fellingham et al. Aug 1990 A
4954818 Nakane et al. Sep 1990 A
4957690 Fennern Sep 1990 A
4961533 Teller et al. Oct 1990 A
4970664 Kaiser et al. Nov 1990 A
4976151 Morishita Dec 1990 A
4978335 Arthur, III Dec 1990 A
4979940 Bobo, Jr. et al. Dec 1990 A
4994035 Mokros Feb 1991 A
4996511 Ohkawa et al. Feb 1991 A
5000739 Kulisz et al. Mar 1991 A
5006997 Reich Apr 1991 A
5009641 Gorton Apr 1991 A
5010473 Jacobs Apr 1991 A
5017059 Davis May 1991 A
5032978 Watson et al. Jul 1991 A
5034004 Crankshaw Jul 1991 A
5038800 Oba Aug 1991 A
5041086 Koenig et al. Aug 1991 A
5047014 Mosebach et al. Sep 1991 A
5047044 Smith et al. Sep 1991 A
5050612 Matsumura Sep 1991 A
5053585 Yaniger Oct 1991 A
5053990 Kreifels et al. Oct 1991 A
5062774 Kramer et al. Nov 1991 A
5069668 Boydman Dec 1991 A
5074756 Davis Dec 1991 A
5078682 Miki et al. Jan 1992 A
5078683 Sancoff et al. Jan 1992 A
5082014 Olichney Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5087245 Doan Feb 1992 A
5088983 Burke Feb 1992 A
5096385 Georgi et al. Mar 1992 A
5098262 Wecker et al. Mar 1992 A
5098409 Stock Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5103211 Daoud et al. Apr 1992 A
5104374 Bishko et al. Apr 1992 A
5111234 Taniguchi et al. May 1992 A
5115223 Moody May 1992 A
5116312 Blankenship et al. May 1992 A
5122820 Pagano et al. Jun 1992 A
5124744 Ogura et al. Jun 1992 A
5124802 Ito et al. Jun 1992 A
5131816 Brown et al. Jul 1992 A
5140862 Pappalardo Aug 1992 A
5153827 Coutre et al. Oct 1992 A
5154700 Danby Oct 1992 A
5155693 Altmayer et al. Oct 1992 A
5157928 Gaudet et al. Oct 1992 A
5168441 Onarheim et al. Dec 1992 A
5172698 Stanko Dec 1992 A
5174472 Raque et al. Dec 1992 A
5176004 Gaudet Jan 1993 A
5181910 Scanlon Jan 1993 A
5190442 Jorritsma Mar 1993 A
5190522 Wojcicki et al. Mar 1993 A
5207642 Orkin et al. May 1993 A
5211626 Frank et al. May 1993 A
5213573 Sorich et al. May 1993 A
5217355 Hyman et al. Jun 1993 A
5219327 Okada Jun 1993 A
5221268 Barton et al. Jun 1993 A
5224051 Johnson Jun 1993 A
5230623 Guthrie et al. Jul 1993 A
5238001 Gallant et al. Aug 1993 A
5241461 Georges Aug 1993 A
5244461 Derlien Sep 1993 A
5244463 Cordner, Jr. et al. Sep 1993 A
5247434 Peterson et al. Sep 1993 A
5256157 Samiotes et al. Oct 1993 A
5265431 Gaudet et al. Nov 1993 A
5267218 Elbert Nov 1993 A
5291190 Scarola et al. Mar 1994 A
5295062 Fukushima Mar 1994 A
5301301 Kodosky et al. Apr 1994 A
5307263 Brown Apr 1994 A
5315530 Gerhardt et al. May 1994 A
5317506 Coutre et al. May 1994 A
5321601 Riedel et al. Jun 1994 A
5338157 Blomquist Aug 1994 A
5339821 Fujimoto Aug 1994 A
5350411 Ryan et al. Sep 1994 A
5353316 Scarola et al. Oct 1994 A
5354273 Hagen Oct 1994 A
5356378 Doan Oct 1994 A
5357427 Langen et al. Oct 1994 A
5363482 Victor et al. Nov 1994 A
5364346 Schrezenmeir Nov 1994 A
5367910 Woodward Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5376070 Purvis et al. Dec 1994 A
5383855 Nicholson et al. Jan 1995 A
5386360 Wilson et al. Jan 1995 A
5388202 Squires et al. Feb 1995 A
5389071 Kawahara et al. Feb 1995 A
5389078 Zalesky et al. Feb 1995 A
5395321 Kawahara et al. Mar 1995 A
5400246 Wilson et al. Mar 1995 A
5412400 Takahara et al. May 1995 A
5429602 Hauser Jul 1995 A
5431627 Pastrone et al. Jul 1995 A
5432709 Vollweiler et al. Jul 1995 A
5440585 Partridge, III Aug 1995 A
5456691 Snell Oct 1995 A
5456692 Smith, Jr. et al. Oct 1995 A
5478211 Dominiak et al. Dec 1995 A
5479643 Bhaskar et al. Dec 1995 A
5481250 Hano Jan 1996 A
5482446 Williamson et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5531697 Olsen et al. Jul 1996 A
5531698 Olsen Jul 1996 A
5537436 Bottoms et al. Jul 1996 A
5558640 Pfeiler et al. Sep 1996 A
5569187 Kaiser Oct 1996 A
5573506 Vasko Nov 1996 A
5582593 Hultman Dec 1996 A
5590648 Mitchell et al. Jan 1997 A
5594786 Chaco et al. Jan 1997 A
5598420 Kaufman Jan 1997 A
5616121 McKay Apr 1997 A
5626144 Tacklind et al. May 1997 A
5630710 Tune et al. May 1997 A
5643212 Coutre et al. Jul 1997 A
5647854 Olsen et al. Jul 1997 A
5658250 Blomquist et al. Aug 1997 A
5658252 Johnson Aug 1997 A
5660176 Iliff Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5681285 Ford et al. Oct 1997 A
5685844 Marttila Nov 1997 A
5687734 Dempsey et al. Nov 1997 A
5695473 Olsen Dec 1997 A
5704366 Tacklind et al. Jan 1998 A
5706458 Koppolu Jan 1998 A
5717603 McClendon et al. Feb 1998 A
5718562 Lawless et al. Feb 1998 A
5719761 Gatti et al. Feb 1998 A
5764159 Neftel Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5781442 Engleson et al. Jul 1998 A
5782805 Meinzer et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5807336 Russo et al. Sep 1998 A
5810771 Blomquist Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5836989 Shelton Nov 1998 A
5857967 Frid et al. Jan 1999 A
5861018 Feierbach Jan 1999 A
5868669 Iliff Feb 1999 A
5871465 Vasko Feb 1999 A
5876370 Blomquist Mar 1999 A
5879143 Cote et al. Mar 1999 A
5879163 Brown et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5895371 Levitas et al. Apr 1999 A
5897493 Brown Apr 1999 A
5899855 Brown May 1999 A
5913310 Brown Jun 1999 A
5918603 Brown Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5933136 Brown Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5940801 Brown Aug 1999 A
5956501 Brown Sep 1999 A
5960403 Brown Sep 1999 A
5966691 Kibre et al. Oct 1999 A
5988851 Gent Nov 1999 A
5997476 Brown Dec 1999 A
6012034 Hamparian et al. Jan 2000 A
6024539 Blomquist Feb 2000 A
6024699 Surwit et al. Feb 2000 A
6032119 Brown et al. Feb 2000 A
6040834 Jain et al. Mar 2000 A
6077055 Vilks Jun 2000 A
6101478 Brown Aug 2000 A
RE36871 Epstein et al. Sep 2000 E
6225999 Jain et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6246992 Brown Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6269340 Ford et al. Jul 2001 B1
6270455 Brown Aug 2001 B1
6406426 Reuss et al. Jun 2002 B1
6420169 Read et al. Jul 2002 B1
6422057 Anderson Jul 2002 B1
6475180 Peterson et al. Nov 2002 B2
6486453 Bales et al. Nov 2002 B1
6551276 Mann et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6671563 Engelson et al. Dec 2003 B1
6689091 Bui et al. Feb 2004 B2
6744350 Blomquist Jun 2004 B2
6749586 Vasko Jun 2004 B2
6765877 Foschiano et al. Jul 2004 B1
6809653 Mann et al. Oct 2004 B1
6852104 Blomquist Feb 2005 B2
6872200 Mann et al. Mar 2005 B2
6882940 Potts et al. Apr 2005 B2
6898540 Davies May 2005 B2
6903743 Ng Jun 2005 B2
6904434 Wallach et al. Jun 2005 B1
6918542 Silverbrook et al. Jul 2005 B2
6936029 Mann et al. Aug 2005 B2
6955915 Fodor et al. Oct 2005 B2
6956572 Zaleski Oct 2005 B2
6979326 Mann et al. Dec 2005 B2
6997920 Mann et al. Feb 2006 B2
6999854 Roth Feb 2006 B2
7004928 Aceti et al. Feb 2006 B2
7024236 Ford et al. Apr 2006 B2
7025743 Mann et al. Apr 2006 B2
7033338 Vilks et al. Apr 2006 B2
7036089 Bauer Apr 2006 B2
7041082 Blomquist et al. May 2006 B2
7042643 Miles May 2006 B2
7073713 Silverbrook et al. Jul 2006 B2
7083108 Silverbrook et al. Aug 2006 B2
7092011 Silverbrook et al. Aug 2006 B2
7097104 Silverbrook et al. Aug 2006 B2
7098803 Mann et al. Aug 2006 B2
7103578 Beck et al. Sep 2006 B2
7109878 Mann et al. Sep 2006 B2
7187404 Silverbrook et al. Mar 2007 B2
7201319 Silverbrook et al. Apr 2007 B2
7234645 Silverbrook et al. Jun 2007 B2
7254782 Sherer Aug 2007 B1
7289142 Silverbrook Oct 2007 B2
7300418 Zaleski Nov 2007 B2
7324012 Mann et al. Jan 2008 B2
7347836 Peterson et al. Mar 2008 B2
7350190 Torres et al. Mar 2008 B2
7358091 Phillips et al. Apr 2008 B2
7362971 Silverbrook et al. Apr 2008 B2
7373083 Silverbrook et al. May 2008 B2
7377706 Silverbrook et al. May 2008 B2
D570363 Ulm et al. Jun 2008 S
D576175 Onodera Sep 2008 S
D580948 Tomizawa et al. Nov 2008 S
7460152 Silverbrook et al. Dec 2008 B2
7471994 Ford et al. Dec 2008 B2
7475825 Silverbrook et al. Jan 2009 B2
7483050 Silverbrook et al. Jan 2009 B2
D586351 Gelman et al. Feb 2009 S
D586357 Jasinski Feb 2009 S
7515060 Blomquist Apr 2009 B2
7524045 Silverbrook et al. Apr 2009 B2
D604741 DeBelser et al. Nov 2009 S
7647237 Malave et al. Jan 2010 B2
7654976 Peterson et al. Feb 2010 B2
7662638 Dadala et al. Feb 2010 B2
7689939 Becker Mar 2010 B1
7708717 Estes et al. May 2010 B2
7713240 Istoc et al. May 2010 B2
7737581 Spurlin et al. Jun 2010 B2
7789859 Estes et al. Sep 2010 B2
7794427 Estes et al. Sep 2010 B2
7801596 Fischell et al. Sep 2010 B2
7815622 Istoc et al. Oct 2010 B2
7860583 Condurso et al. Dec 2010 B2
7861184 Kim et al. Dec 2010 B2
7875022 Wenger et al. Jan 2011 B2
7945452 Fathallah et al. May 2011 B2
7970620 Brown Jun 2011 B2
7981034 Jennewine et al. Jul 2011 B2
8019721 Young et al. Sep 2011 B2
8078983 Davis et al. Dec 2011 B2
8106534 Spurlin et al. Jan 2012 B2
8133197 Blomquist et al. Mar 2012 B2
8149131 Blomquist Apr 2012 B2
8152764 Istoc et al. Apr 2012 B2
8182462 Istoc et al. May 2012 B2
8206296 Jennewine Jun 2012 B2
8250483 Blomquist Aug 2012 B2
8260630 Brown Sep 2012 B2
8287454 Wolpert et al. Oct 2012 B2
8287495 Michaud et al. Oct 2012 B2
8298184 DiPerna et al. Oct 2012 B2
8303518 Aceti et al. Nov 2012 B2
8340792 Condurso et al. Dec 2012 B2
8344847 Moberg et al. Jan 2013 B2
8346399 Blomquist Jan 2013 B2
8380536 Howard et al. Feb 2013 B2
8398592 Leibner-Druska Mar 2013 B2
8407063 Brown Mar 2013 B2
8414557 Istoc et al. Apr 2013 B2
8435206 Evans et al. May 2013 B2
8452953 Buck et al. May 2013 B2
8454581 Estes et al. Jun 2013 B2
8517987 Istoc et al. Aug 2013 B2
8635085 Brown Jan 2014 B2
8663201 Hill et al. Mar 2014 B2
8706691 McDaniel et al. Apr 2014 B2
8881102 Van De Sluis et al. Nov 2014 B2
8926561 Verhoef et al. Jan 2015 B2
8929823 Mears et al. Jan 2015 B2
8952794 Blomquist Feb 2015 B2
9238100 Kruse et al. Jan 2016 B2
9335910 Farnan et al. May 2016 B2
9378333 Blomquist et al. Jun 2016 B2
9381296 Arrizza Jul 2016 B2
9486171 Saint Nov 2016 B2
9669160 Harris Jun 2017 B2
9715327 Rosinko et al. Jul 2017 B2
9814835 Kruse et al. Nov 2017 B2
9833177 Blomquist Dec 2017 B2
9867937 Saint et al. Jan 2018 B2
9867953 Rosinko Jan 2018 B2
9974903 Davis et al. May 2018 B1
9993595 Michaud Jun 2018 B2
10016561 Saint et al. Jul 2018 B2
10052049 Blomquist et al. Aug 2018 B2
10213547 Rosinko Feb 2019 B2
10357603 Michaud Jul 2019 B2
10357606 Rosinko et al. Jul 2019 B2
10357607 Blomquist et al. Jul 2019 B2
10430043 Rosinko et al. Oct 2019 B2
10434253 DiPerna et al. Oct 2019 B2
10549051 Rosinko Feb 2020 B2
10569016 Rosinko Feb 2020 B2
10653834 Kruse et al. May 2020 B2
10726100 Blomquist et al. Jul 2020 B2
20010031944 Peterson et al. Oct 2001 A1
20020029776 Blomquist Mar 2002 A1
20020033840 Masthoff et al. Mar 2002 A1
20020077852 Ford et al. Jun 2002 A1
20020107476 Mann et al. Aug 2002 A1
20020151804 O'Mahony et al. Oct 2002 A1
20020183693 Peterson et al. Dec 2002 A1
20020188627 Bleizeffer Dec 2002 A1
20020193679 Malave et al. Dec 2002 A1
20030011646 Levine et al. Jan 2003 A1
20030060765 Campbell et al. Mar 2003 A1
20030069650 Karmiy et al. Apr 2003 A1
20030114836 Estes et al. Jun 2003 A1
20030139701 White et al. Jul 2003 A1
20030144880 Talachian et al. Jul 2003 A1
20030145053 Bodin et al. Jul 2003 A1
20030160683 Blomquist Aug 2003 A1
20030163088 Blomquist Aug 2003 A1
20030163223 Blomquist Aug 2003 A1
20030163789 Blomquist Aug 2003 A1
20030173408 Mosher, Jr. et al. Sep 2003 A1
20030195974 Ronning et al. Oct 2003 A1
20030204413 Riff Oct 2003 A1
20030204415 Knowlton Oct 2003 A1
20030204416 Radpay et al. Oct 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20040010425 Wilkes et al. Jan 2004 A1
20040065321 Stenzler Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040158193 Bui et al. Aug 2004 A1
20040167465 Mihai et al. Aug 2004 A1
20040172302 Martucci et al. Sep 2004 A1
20040176984 White et al. Sep 2004 A1
20040249673 Smith Dec 2004 A1
20050001797 Miller, IV et al. Jan 2005 A1
20050015731 Mak et al. Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050030164 Blomquist Feb 2005 A1
20050055242 Bello et al. Mar 2005 A1
20050116023 Amundson et al. Jun 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143864 Blomquist Jun 2005 A1
20050144182 Boris et al. Jun 2005 A1
20050160084 Barrett Jul 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050177395 Blomquist Aug 2005 A1
20050183037 Kuenzner Aug 2005 A1
20050246416 Blomquist Nov 2005 A1
20050273080 Paul Dec 2005 A1
20060001550 Mann et al. Jan 2006 A1
20060026205 Butterfield Feb 2006 A1
20060041222 Dewing et al. Feb 2006 A1
20060042633 Bishop et al. Mar 2006 A1
20060073891 Holt Apr 2006 A1
20060079768 Small et al. Apr 2006 A1
20060089542 Sands Apr 2006 A1
20060094985 Aceti et al. May 2006 A1
20060132292 Blomquist Jun 2006 A1
20060202859 Mastrototaro et al. Sep 2006 A1
20060229557 Fathallah et al. Oct 2006 A1
20070060869 Tolle et al. Mar 2007 A1
20070060870 Tolle et al. Mar 2007 A1
20070060871 Istoc et al. Mar 2007 A1
20070066956 Finkel Mar 2007 A1
20070083827 Scott et al. Apr 2007 A1
20070093786 Goldsmith Apr 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070100282 Small et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070129825 Kargenian Jun 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070157089 Van Os et al. Jul 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070253380 Jollota et al. Nov 2007 A1
20070255322 Gerber et al. Nov 2007 A1
20080005700 Morikawa Jan 2008 A1
20080030369 Mann et al. Feb 2008 A1
20080033357 Mann et al. Feb 2008 A1
20080033360 Evans et al. Feb 2008 A1
20080033361 Evans et al. Feb 2008 A1
20080033402 Blomquist Feb 2008 A1
20080033749 Blomquist Feb 2008 A1
20080034323 Blomquist Feb 2008 A1
20080065007 Peterson et al. Mar 2008 A1
20080065016 Peterson et al. Mar 2008 A1
20080065926 Poth et al. Mar 2008 A1
20080071580 Marcus Mar 2008 A1
20080082363 Habashi Apr 2008 A1
20080106431 Blomquist May 2008 A1
20080113292 Matsuo May 2008 A1
20080122796 Jobs et al. May 2008 A1
20080126969 Blomquist May 2008 A1
20080132844 Peterson et al. Jun 2008 A1
20080139910 Mastrototaro et al. Jun 2008 A1
20080155415 Yoon et al. Jun 2008 A1
20080171967 Blomquist et al. Jul 2008 A1
20080172026 Blomquist Jul 2008 A1
20080172027 Blomquist Jul 2008 A1
20080172028 Blomquist Jul 2008 A1
20080172029 Blomquist Jul 2008 A1
20080172030 Blomquist Jul 2008 A1
20080172031 Blomquist Jul 2008 A1
20080189614 Jeong et al. Aug 2008 A1
20080228056 Blomquist et al. Sep 2008 A1
20080269673 Butoi et al. Oct 2008 A1
20080300534 Blomquist Dec 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080300651 Gerber et al. Dec 2008 A1
20080316304 Claus et al. Dec 2008 A1
20090054750 Jennewine Feb 2009 A1
20090113295 Halpern et al. Apr 2009 A1
20090150865 Young et al. Jun 2009 A1
20090156990 Wenger et al. Jun 2009 A1
20090164239 Hayter Jun 2009 A1
20090177180 Rubalcaba, Jr. et al. Jul 2009 A1
20090177991 Davis et al. Jul 2009 A1
20090221890 Saffer et al. Sep 2009 A1
20090227855 Hill et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090275886 Blomquist et al. Nov 2009 A1
20090281393 Smith Nov 2009 A1
20100001064 Goman et al. Jan 2010 A1
20100010330 Rankers et al. Jan 2010 A1
20100010647 Schroeder et al. Jan 2010 A1
20100020064 Roosendaal et al. Jan 2010 A1
20100121415 Skelton et al. May 2010 A1
20100130933 Holland et al. May 2010 A1
20100160759 Celentano Jun 2010 A1
20100174230 Istoc et al. Jul 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100218132 Soni et al. Aug 2010 A1
20100251114 Wehba et al. Sep 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100280486 Khair et al. Nov 2010 A1
20100317950 Galley et al. Dec 2010 A1
20100331651 Groll Dec 2010 A1
20110006876 Moberg et al. Jan 2011 A1
20110009725 Hill et al. Jan 2011 A1
20110009813 Rankers Jan 2011 A1
20110009846 Istoc et al. Jan 2011 A1
20110015509 Peyser Jan 2011 A1
20110082439 Wenger et al. Apr 2011 A1
20110133946 Kopp et al. Jun 2011 A1
20110144586 Michaud et al. Jun 2011 A1
20110144616 Michaud et al. Jun 2011 A1
20110152770 DiPerna et al. Jun 2011 A1
20110152824 DiPerna et al. Jun 2011 A1
20110166544 Verhoef et al. Jul 2011 A1
20110172744 Davis et al. Jul 2011 A1
20110178717 Goodnow et al. Jul 2011 A1
20110184264 Galasso et al. Jul 2011 A1
20110193704 Harper et al. Aug 2011 A1
20110196213 Thukral et al. Aug 2011 A1
20110201911 Johnson et al. Aug 2011 A1
20110213225 Bernstein et al. Sep 2011 A1
20120013625 Blomquist et al. Jan 2012 A1
20120013802 Blomquist et al. Jan 2012 A1
20120029433 Michaud et al. Feb 2012 A1
20120029468 DiPerna et al. Feb 2012 A1
20120030610 DiPerna et al. Feb 2012 A1
20120091813 Spurlin et al. Apr 2012 A1
20120130204 Basta May 2012 A1
20120185267 Kamen et al. Jul 2012 A1
20120232520 Sloan et al. Sep 2012 A1
20130015980 Evans Jan 2013 A1
20130117696 Robertson et al. May 2013 A1
20140012511 Mensinger et al. Jan 2014 A1
20140180711 Kamen et al. Jun 2014 A1
20140200426 Taub et al. Jul 2014 A1
20150119805 Blomquist Apr 2015 A1
20150143356 Charlton et al. May 2015 A1
20160103887 Fletcher et al. Apr 2016 A1
20160199571 Rosinko et al. Jul 2016 A1
20160271325 Farnan et al. Sep 2016 A1
20160328991 Simpson Nov 2016 A1
20160339172 Michaud Nov 2016 A1
20170000943 Blomquist et al. Jan 2017 A1
20170249443 Blomquist et al. Aug 2017 A1
20180042559 Cabrera, Jr. et al. Feb 2018 A1
20180092578 Blomquist Apr 2018 A1
20180110921 Saint et al. Apr 2018 A1
20180193555 Michaud Jul 2018 A1
20180361060 Rosinko Dec 2018 A9
20190121506 Matikyan Apr 2019 A1
20190259485 Blomquist et al. Aug 2019 A1
20190321552 DiPerna et al. Oct 2019 A1
20190328967 Blomquist Oct 2019 A1
20190350501 Blomquist et al. Nov 2019 A1
20190365997 Harris Dec 2019 A1
20190388015 Blomquist Dec 2019 A1
20200012401 Rosinko et al. Jan 2020 A1
20200016335 DiPerna et al. Jan 2020 A1
20200101226 Saint et al. Apr 2020 A1
20200114076 Ulrich et al. Apr 2020 A1
20200171249 Rosinko Jun 2020 A1
20200179603 Rosinko Jun 2020 A1
20200254174 Kruse et al. Aug 2020 A1
20200261649 Michaud et al. Aug 2020 A1
Foreign Referenced Citations (73)
Number Date Country
2060151 Aug 1992 CA
2620229 Jul 2014 CA
665955 Jun 1988 CH
0069350 Jan 1983 EP
0078645 May 1983 EP
0183351 Jun 1986 EP
0188288 Jul 1986 EP
0221005 May 1987 EP
0233115 Aug 1987 EP
0319272 Jun 1989 EP
0328162 Aug 1989 EP
0371507 Jun 1990 EP
0384155 Aug 1990 EP
0408483 Jan 1991 EP
0497041 Aug 1992 EP
0503670 Sep 1992 EP
0371507 Mar 1993 EP
0551088 Jul 1993 EP
0560571 Sep 1993 EP
0806738 Nov 1997 EP
0952541 Oct 1999 EP
1587017 Oct 2005 EP
1647291 Apr 2006 EP
2603488 Mar 1988 FR
2675288 Oct 1992 FR
2039083 Jul 1980 GB
2262452 Jun 1993 GB
2312055 Oct 1997 GB
H09192218 Jul 1997 JP
2002291706 Oct 2002 JP
WO-8403218 Aug 1984 WO
WO-8703814 Jul 1987 WO
WO-8707161 Dec 1987 WO
WO-9116609 Oct 1991 WO
WO-9208647 May 1992 WO
WO-9215439 Sep 1992 WO
WO-9405355 Mar 1994 WO
WO-9408647 Apr 1994 WO
WO-9502426 Jan 1995 WO
WO-9525893 Sep 1995 WO
WO-9528190 Oct 1995 WO
WO-9603168 Feb 1996 WO
WO-9620745 Jul 1996 WO
WO-9636389 Nov 1996 WO
WO-9715227 May 1997 WO
WO-9725083 Jul 1997 WO
WO-9820439 May 1998 WO
WO-9824358 Jun 1998 WO
WO-9842407 Oct 1998 WO
WO-9859487 Dec 1998 WO
WO-9908183 Feb 1999 WO
WO-9910801 Mar 1999 WO
WO-9918532 Apr 1999 WO
WO-9922236 May 1999 WO
WO-0045696 Aug 2000 WO
WO-0048112 Aug 2000 WO
WO-0152727 Jul 2001 WO
WO-0211049 Feb 2002 WO
WO-02069099 Sep 2002 WO
WO-03053503 Jul 2003 WO
WO-03094075 Nov 2003 WO
WO-2005056083 Jun 2005 WO
WO-2005083619 Sep 2005 WO
WO-2006023636 Mar 2006 WO
WO-2006073400 Jul 2006 WO
WO-2008016621 Feb 2008 WO
WO-2008019013 Feb 2008 WO
WO-2008019014 Feb 2008 WO
WO-2008019015 Feb 2008 WO
WO-2008019016 Feb 2008 WO
WO-2008048587 Apr 2008 WO
WO-2009135108 Nov 2009 WO
WO-2011014704 Feb 2011 WO
Non-Patent Literature Citations (102)
Entry
“VBA Conditional Formatting of Charts by Value” Jon Peltier. Mar. 3, 2008. Peltier Technical Services, Inc., Copyright © 2021, Accessed on Jun. 4, 2021 via https://peltiertech.com/vba-conditional-formatting-of-charts-by-value/ (Year: 2008).
510 (k) Registration Documents for Registration of K863997, Document # 87071, Oct. 8, 1986, 84 pages.
510 (k) Registration Documents for Registration of K87022 and K871728, Jul. 27, 1987, 24 pages.
Abbott, “Abbott Literature—Hospital products Division,” in U.S. Appl. No. 08/868,913, Jun. 29, 1998, 37 pages.
Ally™, “Ambulatory Drug Infusion System,” Q-Life Systems Inc, Jun. 29, 1998, 3 pages.
Application and File History for U.S. Appl. No. 16/401,684, filed May 22, 2019, inventors Blomquist, et al.
Application and File History for U.S. Appl. No. 12/114,033, filed May 2, 2008, inventors Blomquist, et al.
Application and File History for U.S. Appl. No. 13/242,045, filed Sep. 23, 2011, inventors Blomquist, et al.
Application and File History for U.S. Appl. No. 13/242,116, filed Sep. 23, 2011, inventors Blomquist, et al.
Application and File History for U.S. Appl. No. 15/407,955, filed Jan. 17, 2017, inventors Blomquist, et al.
“Are Control Rooms Obsolete?,” Advertisement from HERCO, Mar. 1971, 1 page and Mar. 1972, 1 page.
Baxter, “Flo-Guard® 6201 Volumetric Infusion Pump,” Baxter Literature, Copyright 1992, 2 pages.
Baxter, “Literature for Multiplex™ Series 100, Fluid Management System,” Jun. 29, 1998, 4 pages.
Bedder M.D., et al., “Cost Analysis of Two Implantable Narcotic Delivery Systems,” Journal of Pain and Symptom Management, vol. 6(6), Aug. 1991, pp. 368-373.
Bio Tek Instruments, Inc. Products Catalog, Apr. 1992, 32 pages.
Blade-Citizen, “Entrepreneur takes Aim at Home Health Care Market,” Dec. 31, 1989, 2 pages.
“Block Medical: Growing awith Home Infusion Therapy,” In Vivio, The Business and Medicine Report, Apr. 1991, 3 pages.
Bojsen J., et al., “Patient-Controlled Portable Insulin Infusion Pump in Diabetes,” Diabetes, Nov. 1979, vol. 28, pp. 974-979.
Brunetti P., et al., “A Simulation Study on a Self-Tuning Portable Controller of Blood Glucose,” Medical Pathology Institute, Bioengineering Laboratory, Int. J. ArtifOrgans, Jan. 1993, vol. 16(1):51-7, 1 page.
Business, “Portable TV frees patients,” The Orange County Register, Nov. 21, 1991, D Section, 1991, 1 page.
CADD Micro, “Ambulatory Infusion Pump Model 5400,” Operator's Manual for a CADD-Micro™, 1990, front cover and pp. ii-vi, pp. 1-55 (71 pages).
CADD Micro, “Ambulatory Infusion Pump Model 5900,” Operator's Manual for a CADD-Micro™, 1993, Front cover and pp. ii-vi, pp. 1-84 (46 pages).
Calfee R.V., et al., “Effective Control of Blood Pressure by Computerized Infusion of Sodium Nitroprusside,” Clinical Research, 1977, vol. 25, 1 page.
Chisholm D.J., et al., “A Semi-Closed Loop Computer-Assisted Insulin Infusion System: Hospital Use for Control of Diabetes in Patients,” The Medical Journal of Australia, Dec. 8-22, 1984, pp. 13-17.
Chisholm D.J., et al., “A Semi-Closed Loop Computer-Assisted Insulin Infusion System: Hospital Use for Control of Diabetes in Patients,” The Medical Journal of Australia, vol. 141(12-13), Dec. 8-22, 1984, pp. 784-789.
Crone J., et al., “A Programmable Infusion Pump Controller,” 30th Annual Conference on Engineering in Medicine and Biology, Nov. 5-9, 1977 in Los Angeles, California, 11 pages.
Declaration of Anthony C. Roth in Support of Defendant-Counterclaim Plaintiff Smiths Medical Md, Inc. 'S Response Brief to Medtronic Minimed, Inc.'S Claim Construction Brief of U.S. Pat. No. 6,241,704 (Exhibits A-H); C.A. No. 03-776, MedtronicMinimed Inc. v. Smith Medical Md, Inc. Feb. 25, 2005, 173 pages.
Declaration of non-establishment of ISR for International Application No. PCT/US2009/042494 dated Jan. 5, 2010, 2 pages.
Dehne T., “PC-Based Data Acquisition and Instrument Control,” Analytical Chemistry, May 1, 1990, vol. 62(9), pp. 565A, 566A, 568A, 570A, 571A, 572A.
Dertouzos M., “Communications, Computers & Networks,” Scientific American, Sep. 1991, pp. 62-69.
DVD—University of Maryland at College Park MD. Human-Computer Interaction Laboratory, Apr. 1991.
DVD—University of Maryland at College Park MD. Human-Computer Interaction Laboratory, Apr. 1992.
ECRI, “Health Devices,” ECRI A Nonprofit Agency, Dec. 1988, vol. 17(12), 36 pages.
ECRI, “Health Devices,” ECRI A Nonprofit Agency, Dec. 1989, vol. 18(12), 43 pages.
ECRI, “Health Devices,” ECRI A Nonprofit Agency, Dec. 1991, vol. 20(12), 52 pages.
ECRI, “Health Devices,” ECRI A Nonprofit Agency, Mar.-Apr. 1989, vol. 18(3-4), 52 pages.
ECRI, “Health Devices,” ECRI A Nonprofit Agency, Sep. 1991, vol. 20(9), 44 pages.
Findarticles, “Pain Control Devices Gaining Acceptance, Will Expand-Analgesic Delivery Devices-Industry Overview,” retrieved from http://www.findarticles.com/articles/mi_m3498/is_n5_v55/ai_12257770, Sep. 29, 2004, pp. MM341442-MM341445.
Foley J.D., et al., “Fundamentals of Interactive Computer Graphics,” Mar. 1993, pp. 10, 11, 29-35.
Franklin D.F., et al., “The P1073 Medical Informatin Bus,” Oct. 1989, 9 pages.
Gillies G.W.A., et al., “Standard Microcomputer Linked to a Volume-Controlled Infusion Pump for Patient-Controlled Analgesia Research,” Journal of Medical Engineering and Technology, Mar./Apr. 1986, vol. 10(2), pp. 55-57.
Goethel P., “A Better Mousetrap,” San Diego Executive, Sep. 1989, 4 pages.
Hammond J.J., et al., “Hypertensive Crisis Managed by Computer-Controlled Infusion of Sodium Nitroprusside: A Model for the Closed-Loop Administration of Short-Acting Vasoactive Agents,” Computers and Biomedical Research, 1979, vol. 12, pp. 97-108 (1 page).
IMED®, “Gemini® PC-1® Volumetric Infusion Pump/Controller,” Operator's Manual, Aug. 16, 1990, pp. MM341056-MM341094.
IMED, “IMED 980 Volumetric Infusion Pump,” Operator's Manual, 1992, pp. 1-16 (11 pages).
IMED, “IMED Status Infusion Management System,” Jun. 29, 1998, 6 pages.
IMED®, “Model 929 Computer Controlled Volumetric Infusion Pump—Operating Instructions,” Feb. 28, 2008, 21 Pages.
Instruction Manual entitled “Quick Start for Speakerphone XT SD,” copyright 1996.
Instrumentation Newsletter, “Labwindows® 2.0 Extends DOS for Test and Measurement Applications,” National Instruments Instrumentation Newsletter, Nov. 1990, vol. 2(4), 16 pages.
Instrumentation Newsletter, “Measurement and Instrumentation: A vision for the 1990s,” National Instruments Instrumentation Newsletter, Feb. 1991, vol. 3(1), 20 pages.
Instrumentation Newsletter., “National Instruments GPIB Chip Enhances New Generation of Instrument Control,” National Instruments Instrumentation Newsletter, Aug. 1990, vol. 2(3), 20 pages.
Intel®, “28F001BX-T/28F001BX-B 1M(128Kx8) CMOS Flash Memory,” Mar. 1991, 28 pages.
Intel®, “28F008SA 8 MBIT (IMBITx8) Flashtile™ Memory,” Mar. 1992, 28 pages.
International Preliminary Report on Patentability for Application No. PCT/US2009/042494, dated Nov. 11, 2010, 9 pages.
IV700 Service Manual Valleylab, Inc., Boulder, Colorado, Sep. 1988.
Jackson R.V., et al., “Use of a Microprocessor in the Control of Malignant Hypertension with Sodium Nitroprusside,” Aust N Z J Med. Aug. 1977, vol. 7(4), pp. 414-417 (1 page).
Kennelly R.J., “Improving Acute Care Use of Medical Device Data,” Chair IEEE 1073 “Standard for Medical Device Communications” Committee, Eden Shores Consulting, 1992, pp. MM341215-MM341218.
Kern F.H., et al., “Computerized Continuous Infusion of Intravenous Anesthetic Drugs During Pediatric Cardiac Surgery,” Department of Anesthesiology, Duke Heart Center, Duke University Medical Center, Durham, Apr. 1991, vol. 72(4), pp. 487-492 (1 page).
Kouchoukos N.T., et al., “Automated Patient Care Following Cardiac Surgery,” Cardiovascular Clinics, 1971, vol. 3, pp. 110-120.
Labview., “IEEE-488 and VXIbus Control, Data Acquisition, and Analysis,” National Instruments, 1991, cover page and pp. 1-1 through 1-13, 1-38, 4-68 and 4-69.
Labview® 2, “Delivers ease-of-use, Performance, and Flexibility,” National Instruments Instrumentation Newsletter, May 1990, vol. 2(2), 18 pages.
Labview., “Scientific Data Analysis,” National Instruments Document, in U.S. Appl. No. 08/868,913 Jun. 29, 1998, 16 pages.
Labview® 2, “User Manual,” The Front Panel, Jan. 1990 Edition, cover page and pp. 2-1 through 2-36.
Lahti W., et al., “Store Data in a Flash,” Byte, Nov. 1990, pp. 311-318.
Lifecare, “The Blue Line System,” Model 4 Series System brochure, Abott Laboratories, 1990, 16 pages.
Linkens D.A., et al., “Computer Control Systems and Pharmacological Drug Administration: A Survey,” Journal of Medical Engineering & Technology, vol. 14(2), Mar./Apr. 1990, pp. 41-54.
Lord P., et al., “MinMed Technologies Programmable Implantable Infusion System,” Annals of the New York Academy of Sciences, Neurilogical Applications of Implanted Drug Pumps, 1988, pp. 66-71.
Mayhew D.J., “Principles and Guidelines in Software User Interface Design,” Chapter 9 Dialog Styles: Direct Manipulation, 1992, 17 pages.
McCarty L.H., “Software Simulates Instrumentation Systems,” Design News, May 21, 1990, pp. 72-73.
McMorris A.H., et al., “Are Process Control Rooms Obsolete?,” Control Engineering, Jul. 1971, pp. 42-47.
Medtronic Minimed Inc ., “Memorandum Opinion,” C.A. No. 03-776, v. Smiths Medical Md. Inc., Jun. 1, 2005, 64 pages.
Medtronic Minimed, Inc., “Answer and Counterclaims of Smiths Medical Md. Inc.,” (Exhibits 1-5); C.A. 03-776,v. Deltec Inc., Smiths Group North America, Inc. and Smiths Group Pic, Nov. 17, 2003, 536 pages.
Medtronic Minimed, Inc., “Complaint for Patent Infringement,” (Exhibits 1-3); C.A. 03-776,v. Deltec Inc., Smiths Group North America, Inc. and Smiths Group Pic, Aug. 5, 2003, 256 pages.
Medtronic Minimed, Inc., “Declaration of Anthony C. Roth in Support of Defendant-Counterclaim Plaintiff Smiths Medical Md, Inc. 'S Brief in Opposition of Medtronic Minimed Inc. 'S Motion for Summary Judgment of invalidity of claims 6 and 11 of Smiths Medical Inc., U.S. Pat. No. 6,241,704,” (Exhibits 1-7); C.A. 03-7769,v.v. Smith Medical Md, Inc., Feb. 28, 2005, 151 pages.
Medtronic Minimed, Inc., “Defendant Smiths Medical Md, Inc. 'S Brief in Opposition to Medtronic Minimed, Inc 'S Motion for Summary Judgment of Invalidity of Claims 6 and 11 of Smiths Medical Inc. 'S U.S. Pat. No. 6,241,704,” C.A. 03-776,v. Smith Medical Md, Inc., Feb. 28, 2005, 27 pages.
Medtronic Minimed, Inc., “Defendant Smiths Medical Md. Inc. S. Answering Brief Responding to Medtronic Minimed Inc.'S Claim Construction Brief for U.S. Pat. No. 6,241,704,” C.A. 03-776,v. Smith Medical Md, Inc., Feb. 25, 2005, 24 pages.
Medtronic Minimed, Inc., “Expert Report of Jack Goldberg on behalf of Plaintiff Medtronic Minimed Pursuant to Fed R. Civ. P. 26(A)(2),” (Exhibits A-F); C.A. 03-776,v.Smiths Medical Md. Inc. Executed Dec. 15, 2004, 76 pages.
Medtronic Minimed, Inc., “Expert Response of Anthony Storace on behalf of Defendant Conterclaimant Smiths Medical Md., Inc. to the Expert Report Submitted by jack Goldberg on behalf of Plaintiff Medtronic Minimed,” (Exhibits B-J); C.A. No. 03-776, Medtronic Minimed Inc. v.Smiths Medical Md, Inc. Jan. 14, 2005, 143pages.
Medtronic Minimed, Inc., “First Amended Complaint for Patent Infringement,” (Exhibits 1-3); C.A. 03-776,v. Deltec Inc., Smiths Group North America, Inc. and Smiths Group Pic, Nov. 3, 2003, 266 pages.
Medtronic Minimed, Inc., “Joint Claim Construction Statement,” (Exhibits 1-2); C.A. 03-776,Inc. v. Smiths Medical Md, Inc. certificate of service, Feb. 4, 2005, 338 pages.
Medtronic Minimed, Inc., “Medtronic Minimed's Reply Brief in Support of it's Motion for Summary Judgment ofNon-Infringement of Claims 6 and 11 of Smiths '704 Patent,” (Exhibits A-B), Minimed Inc. v. Smiths Medical MD, Inc., Mar. 4, 2005, 34 pages.
Medtronic Minimed, Inc., “Medtronic Minimed's Reply Brief in Support of its Motion for Summary Judgment of Invalidilty of Claims 6 and 11 of Smiths '704 Patent,” (Exhibits A-B); C.A. 03-776,Minimed Inc. v. Smiths Medical MD, Inc., Mar. 4, 2005, 33 pages.
Medtronic Minimed, Inc., “Memorandum Opinion,” C.A. No. 03-776, v. Smiths Medical Md. Inc., Jun. 16, 2005, 17 pages.
Medtronic Minimed, Inc., “Opening Brief in Support of Defendant Smiths Medical, Inc.'S Propsed Claim Constructions for U.S. Pat. No. 6,241,704; U.S. Pat. No. 6,554,065 and U.S. Pat. No. 6,554,798,” (Exhibits 1-20); C.A. 03-776, Medtronic Minimed, Inc. v. Smiths Medical Md, Inc, Feb. 4, 2005, 18 pages.
Medtronic Minimed, Inc., “Order,” C.A. No. 03-776; Medtronic Minimed Inc. v. Smiths Medical Md. Inc., Jun. 1, 2005, 5 pages.
Medtronic MiniMed, “Paradigm Link: Owner's Guide,” BD Logic, 2003, pp. MM341402-MM341441.
Merritt R., “Wireless Hospital Health Care Products on the Upswing,” Jan. 7, 2004, 2 pages.
Motorola Inc., “M68HC11 E Series, HCMOS Microcontroller Unit,” 1993, 1996, 175 pages.
National Instruments, “Lab Windows® 1.2 Materials,” Oct. 1989, 5 pages.
National Instruments, “Lab Windows® 2.0 Materials,” 6 pages.
“Product Overview Verifuse Ambulatory Infusion Pump,” Block Medical Inc, Sep. 1990, 4 pages.
Provider®, “ONE—Instruction Manual,” Panoretec Inc., As submitted on May 18, 1998 in U.S. Appl. No. 08/782,486, 18 pages.
Schneiderman B., “Designing the User Interface,” Chapter 5, Direct Manipulation, Oct. 1993, 57 pages.
Selam J.L., et al., “Devices for Insulin Administration,” Diabetes Care, Sep. 1990, vol. 13(9), pp. 955-979.
Shandie J., “Who Will Dominate the Desktop in the '90s?,” Feb. 1990, 3 pages.
Sheppard L.C ., “Computer Based Clinical Systems: Automation and Integration,” 39th Annual Conference on Engineering in Medicine and Biology, Baltimore, Maryland, Sep. 13-16, 1986, pp. 73-75.
Steinfeld E.F., “Internet-Appllicance Technology Automates Test Equipment,” Oct. 12, 2000, pp. 157-169.
Steinfeld E.F., “Is Embedded Going Net-Crazy??A Response,” Internet Article, Mar. 29, 2001, pp. 1/2.
White M., et al., “Intravenous Propofol Anaesthesia Using a Computerized Infusion System,”Anaesthesia, 1990, vol. 45, pp. 204-209.
Wilson R., “Integrated Circuits” Computer Design, Jun. 1, 1989, pp. 26-27.
Written Opinion for Application No. PCT/US2009/042494, dated Jan. 5, 2010, 7 pages.
Zales S., et al., “Microprocessors and Microsystems,” Oct. 1990, vol. 14(8), pp. 543-549.
Related Publications (1)
Number Date Country
20210012875 A1 Jan 2021 US
Divisions (1)
Number Date Country
Parent 12114033 May 2008 US
Child 13242116 US
Continuations (3)
Number Date Country
Parent 16401684 May 2019 US
Child 17034264 US
Parent 15407955 Jan 2017 US
Child 16401684 US
Parent 13242116 Sep 2011 US
Child 15407955 US